1. Home
  2. OPCH vs ACAD Comparison

OPCH vs ACAD Comparison

Compare OPCH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Option Care Health Inc.

OPCH

Option Care Health Inc.

HOLD

Current Price

$21.66

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$26.20

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPCH
ACAD
Founded
N/A
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.8B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
OPCH
ACAD
Price
$21.66
$26.20
Analyst Decision
Buy
Buy
Analyst Count
7
22
Target Price
$36.57
$30.55
AVG Volume (30 Days)
2.9M
1.7M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
3.25
69.12
EPS
0.29
0.02
Revenue
$4,998,202,000.00
$726,437,000.00
Revenue This Year
$7.21
$18.80
Revenue Next Year
$8.55
$11.70
P/E Ratio
$73.66
$1,288.50
Revenue Growth
16.17
40.45
52 Week Low
$18.01
$19.69
52 Week High
$36.80
$28.35

Technical Indicators

Market Signals
Indicator
OPCH
ACAD
Relative Strength Index (RSI) 50.89 76.95
Support Level $19.61 $25.40
Resistance Level $22.42 $27.79
Average True Range (ATR) 0.70 0.91
MACD 0.08 0.37
Stochastic Oscillator 45.71 82.84

Price Performance

Historical Comparison
OPCH
ACAD

About OPCH Option Care Health Inc.

Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: